Although there are no documented reports of JAK3 inhibitor-based therapy for SLE, we posit that 2D4 may exhibit greater efficacy in autoantibody-mediated autoimmune disease than JAK3 inhibitors. The gene discussed is JAK3; the disease is systemic lupus erythematosus.